ROSG News Alert Rosetta Genomics Ltd (ROSG) 2.35 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Rosetta Genomics Ltd (ROSG) 2.35 $ROSG

PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PFE: 31.42 (-0.03), PTCT: 51.66 (+0.76)

Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.35 (+0.03), ISIS: 59.49 (+1.88), DRNA: 16.23 (-0.23), ALNY: 93.52 (+0.97), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), ALXN: 181.96 (+3.09), TKMR: 13.97 (+0.14), RGLS: 14.78 (+0.24)

Rosetta Genomics to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on December 3, 2014
Business Wire - Tue Nov 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ROSG: 2.35 (+0.03)

Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST

ROSG: 2.35 (+0.03), BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)

Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 2.35 (+0.03)

Rosetta Genomics Announces Publication of Data Demonstrating Differentiation of Adrenocortical Carcinomas from Adenomas by microRNA Profiling
Business Wire - Tue Nov 04, 7:38AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of data relating to the Company's microRNA platform in the online edition of peer-reviewed journal, "Applied Immunohistochemistry and Molecular Morphology." The article entitled, "Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate with Weiss Histopathologic System," highlights the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas with very good correlation with the histologic Weiss system for identifying malignancy in adrenocortical tumors (ACTs). This study is part of a collaborative project between Rosetta Genomics and Prof. Meora Feinmesser, M.D., Head of the Institute of Pathology at the Rabin Medical Center in Israel.
ROSG: 2.35 (+0.03)

Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests
Business Wire - Thu Oct 30, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
ROSG: 2.35 (+0.03)

Rosetta Genomics' microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th Annual Meeting of the American Thyroid Association
Business Wire - Thu Oct 23, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in support of the Company's microRNA-based assay for indeterminate thyroid nodules will be highlighted in a poster presentation entitled, "MicroRNAs as a powerful diagnostic tool for thyroid nodule classification in pre-operative samples," at the upcoming 84th Annual Meeting of the American Thyroid Association (ATA) taking place from October 29th through November 2nd at the Hotel Del Coronado in Coronado, Calif.
ROSG: 2.35 (+0.03)

Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic
Marketwired - Tue Oct 21, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool.
ROSG: 2.35 (+0.03)

Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT

ROSG: 2.35 (+0.03), RNA: 18.76 (+0.10), SRPT: 13.88 (+0.47), PTCT: 51.66 (+0.76)

Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 2.35 (+0.03), BIOC: 2.48 (-0.04)

ROSG, BCOM, ENTR, HEES, LOV, ARI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 24, 3:33AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Rosetta Genomics Ltd (NASDAQ:ROSG), B Communications Ltd (NASDAQ:BCOM), Entropic Communications Inc (NASDAQ:ENTR), H&E Equipment Services Inc (NASDAQ:HEES), Spark Networks Inc (NYSE:LOV), Apollo Commercial Real Estate Finance Inc (NYSE:ARI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 2.35 (+0.03), BCOM: 18.18 (-0.64), ARI: 16.86 (-0.04), HEES: 28.38 (-0.59), LOV: 3.75 (-0.05), ENTR: 2.26 (-0.06)

Market Maker Surveillance Report. NYNY, MOBI, EPIQ, YRCW, ROSG, HPJ, Winning Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Empire Resorts Inc (NASDAQ:NYNY), Sky-mobi Ltd (NASDAQ:MOBI), Epiq Systems Inc (NASDAQ:EPIQ), YRC Worldwide Inc (NASDAQ:YRCW), Rosetta Genomics Ltd (NASDAQ:ROSG), Highpower International Inc (NASDAQ:HPJ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ROSG: 2.35 (+0.03), HPJ: 5.03 (+0.14), EPIQ: 16.99 (-0.22), MOBI: 4.09 (+0.21), NYNY: 7.89 (+0.32), YRCW: 23.52 (-0.15)

Rosetta Genomics Reports Financial Results for the First Half of 2014
eTeligis - Wed Sep 17, 6:56PM CDT
PRINCETON, NJ, United States, via ETELIGIS INC., 09/17/2014 - - Business Update Conference Call to Be Held September 18th at 10:00 a.m. Eastern Time
ROSG: 2.35 (+0.03)

Rosetta Genomics to Host Business Update Conference Call on September 18, 2014
Marketwire - Wed Sep 10, 7:45AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Wednesday, September 17, 2014, the Company will file financial results for the six months ended June 30, 2014 on Form 6-K with the U.S. Securities and Exchange Commission ("SEC" . The Form 6-K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6-K will be available at www.sec.gov and at www.rosettagenomics.com.
ROSG: 2.35 (+0.03)

Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test
Marketwire - Wed Sep 03, 7:19AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the initiation of the Rosetta Cancer Origin Test(TM) Patient Registry study (COPR), a two-part global registry attempting to evaluate the impact of the Cancer Origin Test on treatment decisions in patients diagnosed with metastatic cancers or Cancers of Unknown or Uncertain Primary (CUP). COPR will also attempt to track treatments selected, duration of response to therapies, survival and other clinically relevant information including additional diagnostic testing performed.
ROSG: 2.35 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading

Top 5 Most Recently Viewed Articles

BearingPoint and Swish AI Join Forces to Elevate ITSM Solutions

Updated Category News Views 119

Transforming IT Service Management with AI As digital transformation accelerates, IT service teams encounter challenges like never before. To tackle these issues, management and technology consultancy BearingPoint has formed a significant partnership with Swish AI, a frontrunner in AI-driven IT Service Management (ITSM) solutions. Together, they aim to greatly improve...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 168

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading
Transforming 620 Avenue of the Americas: A New Beginning

Updated Category News Views 97

RXR and Hudson Bay Capital Collaborate on a New Vision The partnership between RXR and Hudson Bay Capital marks an exciting chapter for 620 Avenue of the Americas, a renowned 500,000 square-foot property in the heart of the city. This iconic building is often viewed as a significant piece of real estate, known for its high ceilings and spacious floor plates, becoming a...

Continue Reading
Carolyn Mungo Takes Leadership Role at WFAA and KFAA

Updated Category News Views 230

Carolyn Mungo Takes Leadership Role at WFAA and KFAA TEGNA Inc. (NYSE: TGNA) has exciting news as Carolyn Mungo steps into the role of president and general manager at WFAA, the company’s ABC affiliate, along with KFAA, both serving the vibrant Dallas-Fort Worth area. This transition is effective immediately, marking a new chapter in Mungo's impressive career. A Proven...

Continue Reading
GeoPark Initiates Cash Tender Offer for Senior Notes Redemption

Updated Category News Views 157

GeoPark Starts Cash Tender Offer for Senior Notes GeoPark Limited, a prominent player in the oil and gas sector, has announced that it is launching a cash tender offer for all of its outstanding 5.500% Senior Notes due 2027. This strategic move is designed to improve the company’s capital structure and align its financial resources more effectively. The offering...

Continue Reading